KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Cost of Revenue: 2010-2024

Historic Cost of Revenue for Emergent BioSolutions (EBS) over the last 15 years, with Dec 2024 value amounting to $276.0 million.

  • Emergent BioSolutions' Cost of Revenue fell 29.93% to $85.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.0 million, marking a year-over-year decrease of 144.88%. This contributed to the annual value of $276.0 million for FY2024, which is 9.69% down from last year.
  • Per Emergent BioSolutions' latest filing, its Cost of Revenue stood at $276.0 million for FY2024, which was down 9.69% from $305.6 million recorded in FY2023.
  • In the past 5 years, Emergent BioSolutions' Cost of Revenue registered a high of $748.1 million during FY2021, and its lowest value of $268.5 million during FY2022.
  • In the last 3 years, Emergent BioSolutions' Cost of Revenue had a median value of $276.0 million in 2024 and averaged $283.4 million.
  • Per our database at Business Quant, Emergent BioSolutions' Cost of Revenue skyrocketed by 44.24% in 2020 and then tumbled by 64.11% in 2022.
  • Emergent BioSolutions' Cost of Revenue (Yearly) stood at $537.0 million in 2020, then skyrocketed by 39.31% to $748.1 million in 2021, then slumped by 64.11% to $268.5 million in 2022, then grew by 13.82% to $305.6 million in 2023, then dropped by 9.69% to $276.0 million in 2024.